Acute coronary syndrome in patients with atrial fibrillation: What is the benefit/risk profile of triple antithrombotic therapy?

摘要

Dual antiplatelet therapy is the recommended treatment for all patients with an acute coronary syndrome treated or not treated with an invasive procedure.1-4 Several trials testing clopidogrel or new antiplatelet agents89 clearly showed that the addition of a thyenopiridine to aspirin is associated with a significant improvement of patients' outcomes. Furthermore, even in the case of elective percutaneous coronary procedures, the use of dual antiplatelet therapy is recommended for a medium-long period of time after the procedure.